Stroud, England, United Kingdom
Graham Price, has 15 years experience in clinical development. He is curently Director of Clinical Pharmacology in Global Early Development at UCB, working in the areas of Immunology and Neurology. Most recently he was Chief medical Officer at Oxford BioMedica Ltd, responsible for all medical and clinical research activities leading the clinical development group and accountable for global product development. Prior to this position he was Vice President, Clinical Development for MedImmune Ltd in Cambridge UK, where he was accountable for product development in Europe and Vice President, Clinical Development at Takeda Global R&D where he was global clinical lead for cardiovascular and metabolic products. In addition to extensive R&D experience he has experience of successful management of people, global portfolio management, global product development, clinical projects and alliance management. He has worked in a variety of therapeutic areas including hypertension, heart failure, diabetes, diabetic retinopathy, migraine, immunology, neurology, ophthalmology, oncology, anticoagulation and atherosclerosis. He has experience of clinical programs for small molecules, large molecules, immunotherapy and gene therapy. He has a bachelor’s degree in neuroscience and bachelor’s degrees in Medicine and Surgery from Imperial College of Science Technology and Medicine, London. He is a fellow of the Faculty of Pharmaceutical Medicine . He is a Fellow of the Royal Society of Medicine and has published on various topics including Alzheimer’s disease, hypertension, dyslipidaemia, ocular gene therapy and treatment of cervical malignancy.
Special Advisor to R&D providing strategic counsel, development expert advice and hands‑on contribution and strategic leadership to accelerate the development, optimization, and lifecycle management of pharmaceutical assets while embedding organizational structure and process transformation, digital innovation across global R&D, and commercial functions. The role bridges medical, scientific, operational, organizational and digital domains to maximize asset value, increase operational efficiency, accelerate R&D delivery, speed decision‑making, and drive competitive advantage.
Reporting to Board level. Managing the regulatory affairs, clinical development, biostatistics and data sciences and clinical operations and excellence functions with approximately 700 reports globally. Accountable for the strategy and end to end delivery of the UCB portfolio to launch, including lifecycle management, paediatric programs and post approval commitments.
Reporting to the CMO. Managing the clinical development function with approximately 80 scientists and physicians in US, EU, Japan and China and accountable for the design of end to end clinical development strategies across the UCB portfolio from proof of concept to launch and including lifecycle management, paediatric programs and post approval commitments.
Reporting to the Global Head of Exploratory Development. Responsible for driving early clinical development in the immunology and CNS areas, working with pre-clinical, translational medicine and modelling and simulation colleagues to optimise exploratory development programs and maximise the value of the development candidates across a number of potential indications. Provide senior medical input and leadership to Global Exploratory Development colleagues, Project Leadership Teams, and pre-clinical and research activities.
Currently Consulting at UCB Pharma UK Interim Director of Clinical Strategy, Immunology
Led the EU Clinical development team
Therapeutic Area Head (EU) for the Cardiovascular area, immediately reporting to the Takeda board and globally accountable for strategic clinical development, evaluation of in-licensing opportunities, portfolio management and formulating strategic business plans to bring drugs to market and manage their life cycle. Responsible for a department of 4 medics, 5 scientists and support staff in EU and an extended team of 40 spread over US and Japan. Key achievements in post Completion and MAA/NDA submission of a fixed dose combination program for a line extension in the indication of hypertension. Completion of a 7000 patient program for the prevention and treatment of retinopathy in type 1 and treatment of retinopathy in type 2 diabetes. Completion of Phase III development of a lipid-lowering agent. Establishment of a highly effective transatlantic cardiovascular development department through recruitment of staff in US. Lead Development Division member to corporate restructuring initiative to accommodate new mergers and acquisitions and to respond to the changing internal and external environment of the Takeda business.